The use of biological agents for ankylosing spondylitis will have a certain effect, but the specific effect needs to be judged according to the actual situation of the patient. Biological agents, also known as biotherapeutics or biological response modifiers, are large molecule drugs that are produced and expressed with the help of certain organisms (e.g., microorganisms, plant and animal cells, etc.) by applying gene mutation or DNA recombination technology. They mainly refer to monoclonal antibodies or fusion proteins, which intervene with specific molecules of the body’s immune system and are used to treat immune-mediated inflammatory diseases and tumors with immunosuppressive effects. Representative biologics for the treatment of ankylosing spondylitis mainly include recombinant human type II tumor necrosis factor receptor-antibody fusion protein for injection and adalimumab. Some patients with ankylosing spondylitis are able to relieve the symptoms of spinal joint pain and stiffness after using biological agents, such as recombinant human type II tumor necrosis factor receptor-antibody fusion protein for injection and adalimumab. However, not everyone is suitable for the use of biologics, and some patients do not achieve better results after using biologics, the specific results need to be based on the actual situation. It is recommended that patients with ankylosing spondylitis go to a regular rheumatology and immunology clinic in a timely manner and follow the doctor’s instructions for standardized diagnosis and treatment in order to avoid delaying the condition, and also need to see a doctor regularly for review to avoid other complications.